SSMO statement on Lunsumio

The SSMO takes note of this unprecedented incident with concern. Although follicular lymphoma is a relatively rare form of cancer affecting relatively few patients, it nevertheless raises an important question: how can the health authorities and the pharmaceutical industry ensure that Switzerland does not miss out on new, effective cancer treatments? If this example sets a precedent, cancer patients living in Switzerland would soon be at a disadvantage compared to other countries. The only ray of hope for Lunsumio is that access to this therapy will continue to be possible thanks to a programme for hardship cases initiated by the SSMO called Swiss Patient Access Programme (SPAP). Roche must make the drug available free of charge under the SPAP if two experts appointed by the SSMO independently conclude that a treatment with Lunsumio is indicated.